Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Cystic Fibrosis Foundation | OTHER |
Not provided
Not provided
Not provided
Although early detection and treatment of cystic fibrosis-related diabetes (CFRD) can lead to significant clinical improvements and prolong life, rates of screening are poor likely due to the burdensome nature of oral glucose tolerance testing (OGTT). The investigators propose to assess the feasibility and accuracy of two screening tools, continuous glucose monitoring (CGM) and a home OGTT kit (GTT@home). If this pilot study reveals acceptable accuracy of either device, this study will allow for future studies exploring home-based OGTT screening.
The investigators hypothesize that there will be strong agreement between plasma glucose and glucose as measured by either CGM or GTT@home at three different timepoints during an OGTT: fasting, 1-hour, and 2-hours.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| OGTT Cohort | All enrolled participants will complete an OGTT. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Oral glucose tolerance test | Diagnostic Test | An oral glucose tolerance test will be completed. A fasting glucose will be measured. Participants will drink 1.75 g/kg of dextrose (up to a maximum of 75 grams) within 10 minutes. Glucose values will be measured at 1 hour and 2 hours. |
| Measure | Description | Time Frame |
|---|---|---|
| Agreement between plasma glucose, CGM measured glucose using the Dexcom G7, and GTT@home glucose | Differences in fasting glucose will be measured by the difference in mg/dl between plasma glucose, CGM measured glucose, and GTT@home measured glucose. | Fasting glucose before OGTT |
| Agreement between plasma glucose, CGM measured glucose using the Dexcom G7, and GTT@home glucose | Differences in the 1 hour glucose during the OGTT will be measured by the difference in mg/dl between plasma glucose, CGM measured glucose, and GTT@home measured glucose. | 1 hour mark in OGTT |
| Agreement between plasma glucose, CGM measured glucose using the Dexcom G7, and GTT@home glucose | Differences in the 2 hour glucose during the OGTT will be measured by the difference in mg/dl between plasma glucose, CGM measured glucose, and GTT@home measured glucose. | 2 hour mark in OGTT |
| Measure | Description | Time Frame |
|---|---|---|
| Agreement between the categorical diagnosis of normal glucose tolerance (NGT), impaired glucose tolerance (IGT), indeterminate glycemia (INDET), and CFRD as defined by plasma glucose, CGM glucose, and GTT@home glucose. | Categorical diagnosis of glucose tolerance as measured by plasma glucose, CGM measured glucose using the Dexcom G7, and GTT@home glucose. | Up to 2 hours |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
A total of 15 subjects with cystic fibrosis (CF) over 10 years of age will be approached to participate.
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Children's Hospital of Philadelphia | Philadelphia | Pennsylvania | 19104 | United States |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D003550 | Cystic Fibrosis |
| ID | Term |
|---|---|
| D010182 | Pancreatic Diseases |
| D004066 | Digestive System Diseases |
| D008171 | Lung Diseases |
| D012140 | Respiratory Tract Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| D005951 | Glucose Tolerance Test |
| ID | Term |
|---|---|
| D001774 | Blood Chemical Analysis |
| D019963 | Clinical Chemistry Tests |
| D019411 | Clinical Laboratory Techniques |
| D019937 | Diagnostic Techniques and Procedures |
Not provided
Not provided
Not provided
Not provided
Not provided
|
| Difference between plasma glucose and CGM measured glucose after the fasting glucose | Absolute differences between the glucose measurements will be measured in mg/dL | Up to 20 minutes after the fasting glucose |
| Difference between plasma glucose and CGM measured glucose after the 1 hour mark during the OGTT. | Absolute differences between the glucose measurements will be measured in mg/dL | Up to 20 minutes after the 1 hour mark in the OGTT |
| Difference between plasma glucose and CGM measured glucose after the 2 hour mark during the OGTT. | Absolute differences between the glucose measurements will be measured in mg/dL | Up to 20 minutes after the 2 hour mark in the OGTT |
| The ability of untrained participants to successfully complete the GTT@home kit without any guidance from the research team | Number of steps successfully completed as measured by the GTT@home instruction manual. | Up to 2 hours |
| Impact of wearing a real-time CGM on participants' awareness of the importance of screening for and diagnosing CFRD. | 60 minute semi-structured interviews will be conducted with participants. Transcripts will be analyzed using semantic content analysis | Within 2 weeks after removal of the CGM |
| Perceived benefits and burdens of CGM use | Participants will complete a CGM Benefits and Burdens survey, a 16-item measure used to assess perceptions of CGM technology in people with type 1 diabetes. Surveys may be completed on paper or online, as per the participant's preference. The survey is scored on a 5-point scale (agree/disagree scale). | Within 2 weeks after removal of the CGM |
| D030342 |
| Genetic Diseases, Inborn |
| D009358 | Congenital, Hereditary, and Neonatal Diseases and Abnormalities |
| D007232 | Infant, Newborn, Diseases |
| D003933 | Diagnosis |
| D003940 | Diagnostic Techniques, Endocrine |
| D008919 | Investigative Techniques |